Benzinga | Sep 21, 2021 04:35AM EDT

SVB Leerink Maintains Outperform on Mirati Therapeutics, Raises Price Target to $205

SVB Leerink analyst Andrew Berens maintains Mirati Therapeutics (NASDAQ:MRTX) with a Outperform and raises the price target from $195 to $205.